3
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
145
Stomach Neoplasms
22
Triple Negative Breast Neoplasms
21
Inflammatory Breast Neoplasms
14
Carcinoma, Hepatocellular
13
Esophageal Neoplasms
11
Lymphoma, Large B-Cell, Diffuse
7
Neoplasms
6
Pancreatic Neoplasms
5
Urinary Bladder Neoplasms
4
Adenocarcinoma Of Esophagus
4
Testicular Neoplasms
3
Sarcoma
3
Primary Breast Cancer
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Non-Muscle Invasive Bladder Neoplasms
3
Liver Neoplasms
3
Gallbladder Neoplasms
3
Carcinoma, Ductal, Breast
3
Breast Neoplasms, Male
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Recurrence
2
Pathologic Complete Response
2
Neoplastic Cells, Circulating
2
Neoplasms, Germ Cell and Embryonal
2
HER2-negative Breast Cancer
2
Carcinoma, Adenoid Cystic
2
Breast Diseases
2
pCR Rate
1
Women With Primary Breast Cancer
1
Interventions
Gemcitabine
58
Cisplatin
41
Capecitabine
27
Oxaliplatin
25
durvalumab
16
Fluorouracil
16
Leucovorin
15
S 1 (combination)
11
lenvatinib
10
Nivolumab
10
Irinotecan
10
pembrolizumab
8
apatinib
8
Immune Checkpoint Inhibitors
7
130-nm albumin-bound paclitaxel
7
tremelimumab
6
Bevacizumab
6
camrelizumab
5
Trastuzumab
5
Drug Therapy
5
Blood Specimen Collection
5
Albumin-Bound Paclitaxel
5
tislelizumab
4
irinotecan sucrosofate
4
Taxes
4
Liquid Biopsy
4
Folfox protocol
4
toripalimab
3
surufatinib
3
gemcitabine-oxaliplatin regimen
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Biliary Tract Neoplasms
×
Epirubicin
×
Clear all
NCT03668418
2018-09-12
xenoZ
University of Pisa
Unknown
120 enrolled